Risk–benefit of rotavirus vaccination by country on rotavirus hospitalisations and deaths and associated intussusception risk for one vaccinated birth cohort to age 5 years
| Country | Vaccine evaluated | Vaccine dose(s) | Overall attributable risk* | Rotavirus outcomes averted | Intussusception outcomes caused |
| Mexico34 | Rotarix | Dose 1 only | 2.0–3.7 | Hospitalisations: 11 551 Deaths: 663 | Hospitalisations: 41 Deaths: 2 |
| Brazil34 | Rotarix | Dose 2 only | 1.5 | Hospitalisations: 69 572 Deaths: 640 | Hospitalisations: 55 Deaths: 3 |
| Australia35 | Rotarix | Doses 1 and 2 | 4.3 | Hospitalisations: 6528 Deaths: not reported | Hospitalisations: 14 Deaths: not reported |
| RotaTeq | Doses 1 and 2 | 7.0 | |||
| USA36 39 | Rotarix | Doses 1 and 2 | 5.3 | Hospitalisations: 53 444 Deaths: 14 | Hospitalisations: 35–166 Deaths: 0.1–0.5 |
| Dose 2 only | 7.3 | ||||
| RotaTeq | Dose 1 only | 0.7–1.5 | Not reported | Not reported | |
| England40 | Rotarix | Dose 1 only | 1.68 | Hospitalisations: 25 000 Deaths: not reported | Hospitalisations: 21 Deaths: not reported |
Note: Table adapted from Reference.87
*Excess intussusception cases per 100 000 vaccinated infants.